Journal
CEN CASE REPORTS
Volume 10, Issue 1, Pages 83-87Publisher
SPRINGER JAPAN KK
DOI: 10.1007/s13730-020-00524-3
Keywords
Coronavirus; COVID-19; Immunosuppression; Membranous nephropathy; Rituximab
Categories
Ask authors/readers for more resources
During the COVID-19 pandemic, striking a balance between combating the outbreak and treating patients with chronic diseases is crucial.
While COVID-19 pandemic continues to affect our country and most countries in the world, we have to make some changes both in our social life and our approach to healthcare. We have to struggle with the pandemic on one hand and also try to follow up and treat our patients with chronic diseases in the most appropriate way. In this period, one of our group of patients who are challenging us for follow-up and treatment are those who should start or continue to use immunosuppressive therapy. In order to contribute to the accumulation of knowledge in this area, we wanted to report a patient who was followed up with the diagnosis of COVID-19 and had been administered rituximab very recently due to a nephrotic syndrome caused by membranous nephropathy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available